Botanix Pharmaceuticals / Sofdra Launch


Refills are above 97% month on month. Clients are not in the habit of cancelling, mainly because Sofdra is working.

Can't give you exact figures, but let's just say somewhere in between 3% - 7% of the market is already ours. Have seen multiple big wigs from places I cannot say meet with management. TO is coming.
Interesting - do you mean 3-7% of prescribers or actual patient TAM? That would be a huge number already. Wondering what base you’re using.
 








Let’s all stay grounded—there’s no need for exaggeration or speculation. Since the end of December 2024, we've reached over 18,000 patients, and based on current momentum, we’re on track to hit around 70,000 by year’s end. The product is performing exceptionally well and demand continues to grow. We're not just aiming to meet our sales targets—we’re on pace to exceed them. That success will translate into the recognition and rewards we expect.


I know this forum is closely followed by a number of Australian investors, and as I’ve said before, the upcoming sales results due in July will back this up—clear, hard evidence of what we’ve been saying all along.
 






























This is the final update I will ever make here. Refill rates are exceed 82% month on month for last 6 months since December. Of those who have not completed their refills, the vast majority had insurance or employment issues. There is a very, very little amount of whom actually stopped using it for other reasons. Take care.
 



Write your reply...